Willow Bracket

Metadata

Regulatory Status

Russia and Siberia

• Traditional medicine: Phellinus igniarius (Trutovik) has been used in Russian and Siberian folk medicine for centuries. It was historically used to prepare a decoction or tea for gastrointestinal complaints, as a topical wound treatment (processed trama applied as styptic material, similar to Fomes fomentarius), and as part of traditional cancer remedies among indigenous Siberian peoples. The tradition parallels but is distinct from the use of Chaga (Inonotus obliquus), which grows in the same birch forest ecosystem.
• Pharmacopoeia status: Not listed in the Russian State Pharmacopoeia as an official drug. However, historical Russian ethnobotanical literature documents its medicinal use extensively.
• Cultural significance: Among Siberian indigenous peoples, including Khanty and Mansi communities, various Hymenochaetaceae bracket fungi were used medicinally, though precise species distinctions were not made in traditional knowledge systems.

China

• Traditional use: Used in traditional Chinese folk medicine (distinct from the formal TCM pharmacopoeia tradition) for various inflammatory and gastrointestinal conditions. Often conflated with or used interchangeably with Phellinus linteus and Sanghuangporus sanghuang in regional folk practice.
• Chinese Pharmacopoeia: Not listed. The taxonomic confusion between P. igniarius, P. linteus, and Sanghuangporus sanghuang has historically complicated the regulatory classification of “Sanghuang”-type fungi in China.

Korea

• Traditional use: Historically referenced in Korean traditional medicine under names related to “Sang-Hwang” (though this name more properly applies to Sanghuangporus sanghuang and Phellinus linteus). The taxonomic confusion between Phellinus species in Korean traditional medicine mirrors that in Chinese practice.

United States

• FDA status: Not approved as a drug. Not specifically marketed as a dietary supplement. Some “Phellinus” or “Meshima” products may contain P. igniarius material without species authentication.
• No GRAS determination.

European Union

• Novel food status: Not authorized. No specific evaluation.
• No EMA/HMPC monograph.
• Ethnobotanical tradition: Documented use in Northern and Eastern European folk medicine, particularly in Scandinavian and Russian traditions.

Conditions & Indications

Primary: Immunomodulation and Anti-Tumor Activity (Preclinical Evidence)

• Anti-tumor polysaccharides: Beta-glucan polysaccharides isolated from P. igniarius fruiting bodies demonstrate significant anti-tumor activity in animal models (sarcoma 180 in mice). The mechanism involves both direct anti-proliferative effects and indirect immunostimulatory effects, with enhancement of macrophage, NK cell, and T-lymphocyte activity. Tumor inhibition rates of 60-85% have been reported in murine sarcoma models, though these results have not been validated in human studies.
• Hispolon anti-tumor activity: Hispolon, the signature styrylpyrone compound of P. igniarius, demonstrates cytotoxicity against multiple cancer cell lines including human gastric cancer (NCI-N87), breast cancer (MCF-7), and hepatocellular carcinoma (HepG2). Mechanisms include apoptosis induction through ROS generation and mitochondrial pathway activation, cell cycle arrest at G2/M phase, and inhibition of the NF-kB signaling pathway.
• Immunomodulation: Polysaccharide fractions stimulate innate immune responses through macrophage activation, enhanced phagocytic activity, and increased production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IFN-gamma). These effects parallel the immunomodulatory activity documented for other Hymenochaetaceae species including P. linteus and Inonotus obliquus.

Secondary: Anti-Inflammatory and Antioxidant Effects (Preclinical Evidence)

• Anti-inflammatory activity: Hispolon and phenolic compounds suppress NF-kB-mediated inflammatory signaling, reducing production of NO, PGE2, and pro-inflammatory cytokines in LPS-stimulated macrophage models. Hispolon specifically inhibits TNF-alpha-induced NF-kB activation in a dose-dependent manner.
• Antioxidant activity: The phenolic compound profile (protocatechuic acid, caffeic acid, hispidin) provides significant free radical scavenging capacity. Both ethanol and aqueous extracts demonstrate DPPH, ABTS, and superoxide radical scavenging activity. Metal chelation activity (Fe2+ and Cu2+) contributes to the antioxidant profile by preventing Fenton reaction-mediated oxidative damage.
• Wound healing support: The historical use as a wound treatment in Siberian and European folk medicine is supported by the antimicrobial and anti-inflammatory bioactive profile, though modern wound healing studies have not been conducted.

Emerging/Preclinical

• Antimicrobial activity: Interfungins A-C, furanone derivatives isolated from P. igniarius, demonstrate antibacterial activity against Gram-positive bacteria including Staphylococcus aureus and Bacillus subtilis. Ethanol extracts show broad-spectrum antimicrobial activity against additional bacterial and fungal pathogens.
• Anti-diabetic potential: Hispolon and ethanol extracts demonstrate alpha-glucosidase inhibitory activity in vitro, suggesting potential for managing postprandial hyperglycemia. This activity has not been investigated in animal models of diabetes.
• Hepatoprotective effects: Ethanol and aqueous extracts demonstrate protective effects against chemically induced hepatocyte damage in vitro, reducing markers of liver injury and oxidative stress.
• Anti-angiogenic activity: Hispolon has been reported to inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis in preclinical models, a mechanism relevant to both cancer therapy and chronic inflammatory conditions.

Mechanism of Action

Primary Mechanisms

1. Hispolon-mediated NF-kB inhibition and apoptosis induction: Hispolon (6-(3,4-dihydroxyphenyl)-4-hydroxy-2H-pyran-2-one) is the most pharmacologically characterized compound from P. igniarius. It exerts anti-tumor effects through multiple convergent mechanisms: (a) inhibition of NF-kB signaling by preventing IkB-alpha phosphorylation and degradation, thereby blocking nuclear translocation of NF-kB and reducing transcription of anti-apoptotic genes (Bcl-2, Bcl-xL, survivin); (b) induction of mitochondrial apoptosis through ROS generation, cytochrome c release, and caspase-3/9 cascade activation; (c) G2/M cell cycle arrest through modulation of cyclin B1 and CDK1 expression. The NF-kB inhibitory mechanism also underlies hispolon’s anti-inflammatory activity, as NF-kB is a master regulator of both inflammatory and anti-apoptotic gene transcription.

2. Polysaccharide-driven innate immune activation: Beta-1,3/1,6-D-glucan polysaccharides from P. igniarius activate innate immune cells through Dectin-1 and TLR-2/TLR-4 pattern recognition receptors on macrophages, dendritic cells, and NK cells. Receptor engagement triggers downstream NF-kB and MAPK signaling cascades, resulting in enhanced phagocytic activity, cytokine production (TNF-alpha, IL-1beta, IL-6, IL-12, IFN-gamma), and augmented NK cell cytotoxicity. This dual mechanism — hispolon directly inhibiting NF-kB in tumor cells while polysaccharides activate NF-kB in immune cells — exemplifies the context-dependent pharmacology of medicinal mushroom preparations.

3. Styrylpyrone antioxidant network: Hispolon and hispidin (a related styrylpyrone) function as potent phenolic antioxidants through direct radical scavenging (the catechol moiety of hispolon is particularly effective), metal chelation (preventing Fenton chemistry), and upregulation of endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase). The styrylpyrone class of compounds is characteristic of Hymenochaetaceae fungi and provides a distinctive antioxidant mechanism not found in most other medicinal mushroom families.

Secondary Mechanisms

• Interfungin antimicrobial activity: Interfungins A-C disrupt bacterial cell membrane function, providing antibacterial activity particularly against Gram-positive organisms. The furanone structural class has attracted interest for potential anti-biofilm activity, though this specific application has not been investigated for P. igniarius-derived compounds.
• VEGF-mediated anti-angiogenesis: Hispolon inhibits VEGF-receptor signaling in endothelial cells, reducing new blood vessel formation. This mechanism is relevant to cancer progression (tumor angiogenesis) and potentially to chronic inflammatory conditions characterized by pathological angiogenesis.
• Alpha-glucosidase inhibition: Hispolon and related phenolics demonstrate competitive inhibition of alpha-glucosidase, reducing postprandial glucose absorption. The IC50 values are moderate and the clinical significance is unknown.

Key Active Compounds

Clinical Evidence Summary

No human clinical trials have been published specifically for Phellinus igniarius. The clinical evidence base consists of extensive Siberian and European ethnobotanical records combined with modern preclinical pharmacological studies.

Ethnobotanical Evidence

Preclinical Evidence Summary

Evidence Limitations

• No human clinical trials. This is the most critical limitation. All modern pharmacological evidence derives from in vitro cell culture and animal model studies.
• Taxonomic confusion. The historical concept of Phellinus igniarius encompassed a species complex now split into multiple distinct species. Literature published before ~2000 may refer to different biological species under the same name, complicating evidence synthesis.
• Conflation with P. linteus and Sanghuangporus. In Korean and Chinese traditional medicine, various Hymenochaetaceae bracket fungi have been used under overlapping common names. Some literature attributed to “P. igniarius” may actually concern P. linteus, S. sanghuang, or other species. This is a significant barrier to evidence evaluation.
• Hispolon is not unique to P. igniarius. Hispolon is also found in P. linteus and other Hymenochaetaceae species. Studies on hispolon pharmacology may derive from P. linteus sources and cannot be automatically attributed to P. igniarius products.
• Limited in vivo data. Most preclinical evidence is from in vitro studies. The animal model data (primarily sarcoma 180 in mice) use an artificial tumor system that does not closely model human cancer.
• Oral bioavailability unknown. The pharmacokinetics of hispolon after oral administration in humans have not been characterized. In vitro potency may not translate to in vivo efficacy.

Safety Profile

General Assessment

Phellinus igniarius has a long history of traditional use in Siberian and Eastern European folk medicine, suggesting general tolerability. The perennial fruiting body has been consumed as a tea/decoction for centuries. However, no formal safety evaluation has been conducted in controlled human studies. Preclinical studies report selective cytotoxicity of hispolon against cancer cell lines with relatively low toxicity to normal cells, but this does not constitute a comprehensive safety assessment.

Contraindications

• Pregnancy and lactation: No safety data. Avoid until safety is established.
• Polypore allergy: Individuals with known allergy to Hymenochaetaceae or polypore fungi should avoid use.
• Autoimmune disease: Theoretical concern that polysaccharide-driven immunostimulatory effects could exacerbate autoimmune conditions. Clinical evidence for this interaction is absent, but the theoretical basis is consistent with other immunomodulatory polypore species.

Drug Interactions

• No documented drug interactions in human use.
• Theoretical immunosuppressant interaction: Polysaccharide immunostimulatory activity may counteract immunosuppressive therapy. Use with caution in transplant patients.
• Theoretical anticoagulant interaction: Some Hymenochaetaceae species demonstrate antiplatelet or fibrinolytic activity. No specific data for P. igniarius, but caution is advised with concurrent anticoagulant therapy.
• Theoretical chemotherapy interaction: Hispolon’s NF-kB inhibitory activity could theoretically interact with certain chemotherapy regimens that depend on NF-kB-mediated apoptosis pathways. This is speculative and not documented.

Side Effects

• Not systematically characterized in human studies.
• Traditional use reports suggest general tolerability when consumed as a tea/decoction. Gastrointestinal discomfort is the most likely adverse effect based on analogy with other medicinal polypore preparations.
• Allergic reactions possible in fungal-sensitive individuals.

Toxicology

• Preclinical toxicity: Limited data available. Hispolon shows selective cytotoxicity with preferential activity against cancer cell lines over normal cell lines in vitro.
• No LD50 data available for oral consumption.
• Heavy metals: Wild-harvested bracket fungi can bioaccumulate heavy metals from host trees and soil. Testing is advised for products intended for human consumption.
• Species authentication: Given the taxonomic complexity of the Phellinus sensu lato group, molecular verification of species identity is essential for any medicinal product.

Clinical Dosage

Traditional Preparations (Historical Reference)

• Decoction: In Siberian and Russian folk medicine, pieces of dried P. igniarius fruiting body were simmered in water for 1-2 hours to make a medicinal tea. No standardized dose was documented, but traditional use patterns suggest quantities comparable to Chaga preparations (3-10 g dried material per decoction).
• Topical wound dressing: The processed trama (inner fibrous layer) was applied directly to wounds as a styptic bandage, similar to amadou from Fomes fomentarius. This was an external application.

Modern Preparations (No Established Dosage)

• Dried fruiting body powder: No clinically validated dose. By analogy with other medicinal polypore preparations, 1-5 g/day of dried powder has been suggested, but this is empirical.
• Hot-water extract: No standardized dosing. Would extract primarily the polysaccharide fraction.
• Ethanol extract: Would capture hispolon and other styrylpyrone compounds. No human dosing data.
• Dual extraction: Hot water plus ethanol would capture both polysaccharides and styrylpyrones. No validated human dose.

Critical Note

No human clinical trials have established safe or effective doses for P. igniarius. All suggested doses are provisional, based on traditional use patterns and analogy with other medicinal polypore species. Species authentication is critical given the taxonomic complexity of the Phellinus sensu lato group. Individuals considering use should seek practitioner guidance and use authenticated, quality-tested products.

Sources

• Chen YS, Lee SM, Lin CC, Liu CY. Hispolon decreases melanin production and induces apoptosis in melanoma cells through the downregulation of tyrosinase and microphthalmia-associated transcription factor (MITF) expressions and the activation of caspase-1, -3 and -9. Int J Mol Sci. 2014;15(1):1201-1215
• Lu TL, Huang GJ, Lu TJ, Wu JB, Wu CH, Yang TC, Iizuka A, Chen YF. Hispolon from Phellinus linteus has antiproliferative effects via MDM2-recruited ERK1/2 activity in breast and bladder cancer cells. Food Chem Toxicol. 2009;47(8):2013-2021
• Shao HJ, Jeong JB, Kim KJ, Lee SH. Anti-inflammatory activity of mushroom-derived hispidin through blocking of NF-kB activation. J Sci Food Agric. 2015;95(12):2482-2486
• Huang HY, Chieh SY, Tso TK, Chien TY, Lin HT, Tsai YC. Orally administered mycelial culture of Phellinus linteus exhibits antitumor effects in hepatoma-bearing mice. J Ethnopharmacol. 2011;133(2):460-466
• Wu SH, Dai YC, Hattori T, Yu TW, Wang DM, Parmasto E, Chang HY, Shih SY. Species clarification for the medicinally valuable ‘sanghuang’ mushroom. Bot Stud. 2012;53:135-149
• Dai YC, Zhou LW, Cui BK, Chen YQ, Decock C. Current advances on Phellinus sensu lato: medicinal species, functions, metabolites and mechanisms. Appl Microbiol Biotechnol. 2010;87(5):1587-1593
• Jang BS, Kim JC, Bae JS, Rhee MH, Jang KH, Song JC, Kwon OD, Park SC. Extracts of Phellinus gilvus and Phellinus baumii inhibit platelet aggregation in vitro and in vivo. Evid Based Complement Alternat Med. 2012;2012:871278
• Ali NAA, Mothana RAA, Lesnau A, Pilgrim H, Lindequist U. Antiviral activity of Inonotus hispidus. Fitoterapia. 2003;74(5):483-485
• Wagner R, Mitchell DA, Sassaki GL, Amazonas MA. Current techniques for the cultivation of Ganoderma lucidum for the production of biomass, ganoderic acid and polysaccharides. Food Technol Biotechnol. 2003;41(4):371-382
• Grienke U, Zoll M, Peintner U, Rollinger JM. European medicinal polypores — a modern view on traditional uses. J Ethnopharmacol. 2014;154(3):564-583
• Papp N, Rudolf K, Bencsik T, Czegeny D. Ethnomycological use of Fomes fomentarius (L.) Fr. and Piptoporus betulinus (Bull.) P. Karst. in Transylvania, Romania. Genet Resour Crop Evol. 2017;64(1):101-111
• Shikov AN, Tsitsilin AN, Pozharitskaya ON, Makarov VG, Heinrich M. Traditional and current food use of wild plants listed in the Russian Pharmacopoeia. Front Pharmacol. 2017;8:841
• Huang GJ, Huang SS, Deng JS. Anti-inflammatory activities of inotilone from Phellinus linteus through the inhibition of MMP-9, NF-kB, and MAPK activation in vitro and in vivo. PLoS One. 2012;7(5):e35922
• Kim JH, Kim SJ, Lee IK, Yun BS. Hispidin derivatives from the mushroom Inonotus xeranticus. J Nat Prod. 2013;76(5):950-953

Connections

• Phellinus linteus (Meshima): Phellinus linteus is the most closely related well-studied species and shares hispolon as a key bioactive compound. P. linteus has significantly more clinical research, including human studies on immune modulation in cancer patients in Korea and Japan. Evidence from P. linteus informs expectations for P. igniarius pharmacology but cannot be directly extrapolated due to species-level differences in bioactive concentrations and profiles.
• Sanghuangporus sanghuang: Sanghuangporus sanghuang has been taxonomically separated from the Phellinus sensu lato complex and represents another medicinally important species within the same family. The historical conflation of “Sanghuang” names across P. igniarius, P. linteus, and S. sanghuang in traditional East Asian medicine is a significant barrier to evidence-based use of these species.
• Inonotus obliquus (Chaga): Chaga shares the birch forest habitat and Hymenochaetaceae family membership with P. igniarius. Both species were used in Siberian folk medicine, sometimes by the same communities, for overlapping indications. Chaga has substantially more modern research and commercial development, but P. igniarius offers a complementary bioactive profile centered on styrylpyrones rather than betulinic acid derivatives.
• Inonotus hispidus (Shaggy Bracket): Inonotus hispidus is another Hymenochaetaceae medicinal species with hispidin-type styrylpyrone compounds, demonstrating the family-level importance of this chemical class for medicinal applications.
• Fomes fomentarius (Tinder Fungus): Tinder Fungus shares the historical use as a wound dressing material (processed trama) in European folk medicine. Both species served as tinder for fire-starting, leading to overlapping common names (“tinder fungus” vs. “false tinder fungus”). They represent parallel ethnomedicinal traditions across Northern Hemisphere cultures.
• Turkey Tail (Trametes versicolor): Turkey Tail shares the polysaccharide-driven immune modulation mechanism and represents the gold standard for clinical evidence in medicinal mushroom immunotherapy. The PSK/Krestin clinical model from Japan provides a template for how P. igniarius polysaccharides could potentially be developed for clinical use.